PIK3CA and breast carcinoma: Given the aforementioned findings, the approach Novartis has taken in breast cancer has been to develop trials that are adequately powered to prospectively investigate efficacy in both the population as a whole and in the subpopulation of patients with PI3K pathway alterations.